Home
contact us  /  email
about us
portfolio
team
news
Aug 01, 2019
Take Your Medicine: This $1.5 Billion Health Startup’s Smart Pills Keep Patients From Forgetting
Forbes
Angel Au-Yeung explores Proteus' ingestible sensors to track medicine intake   more >>
Jul 29, 2019
Coherus BioSciences Reports Victory in Pegfilgrastim Patent Dispute
Coherus BioSciences, Inc.
Coherus BioSciences, Inc. today announced that the United States Court of Appeals for the Federal Circuit has affirmed the decision of the United States District Court for the District of Delaware that Coherus’ UDENYCA® does not infringe Amgen’s asserted patent.   more >>
Nov 02, 2018
U.S. FDA Approves UDENYCA™
Coherus BioSciences, Inc.
Coherus BioSciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved UDENYCA™ (pegfilgrastim-cbqv), the first pegfilgrastim biosimilar approved by both the FDA and the European Commission (EC) for patients with cancer receiving myelosuppressive chemotherapy.   more >>
Oct 11, 2018
Otsuka and Proteus sign 5-year, $88M digital pill partnership
Fierce Biotech
Otsuka Pharmaceutical and Proteus Digital Health have re-upped their global smart-tablet partnership for another five years, aiming to develop a new generation of ingestible sensors.   more >>
Sep 25, 2018
Coherus Biosciences receives European Commission approval for udenyca™ (pegfilgrastim biosimilar)
GLOBE NEWSWIRE
Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar.   more >>
Sep 11, 2018
Invuity announces definitive agreement to be acquired by Stryker Corporation for $7.40 per share in cash
GLOBE NEWSWIRE
Invuity, Inc. (NASDAQ: IVTY), a leading medical technology company focused on advanced surgical devices to enable better visualization, today announced it has entered into a definitive agreement with Stryker Corporation (NYSE:SYK), pursuant to which Stryker will acquire all of the outstanding shares of Invuity for $7.40 per share in cash   more >>
Nov 14, 2017
The Digital Pill Era Is Here — And It Could Help Solve a $300 Billion Health Care Problem
Fortune
The Food and Drug Administration (FDA) on 11/13/2017 approved the first ever drug-digital tracking tool hybrid for the U.S. market.   more >>
Nov 16, 2015
Invuity, Inc. (Nasdaq: IVTY) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire
Invuity, Inc. (IVTY), an advanced medical technology company focused on developing Intelligent Photonics™ devices will visit the Nasdaq MarketSite in Times Square in celebration of both its initial public offering earlier this year and the successful launch of its Hidden Scar™ Surgery program for breast cancer surgery, a part of the company's broader women's health initiative.   more >>
Jun 11, 2015
Invuity Announces Pricing of Initial Public Offering
PR Newswire
SAN FRANCISCO, June 11, 2015 /PRNewswire/ -- Invuity, Inc. today announced the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts and commissions   more >>
Nov 06, 2014
Coherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock
Globe Newswire
Coherus BioSciences, Inc. (Nasdaq:CHRS) announced today the pricing of its initial public offering of 6,296,300 shares of its common stock at a public offering price of $13.50 per share   more >>
Apr 11, 2013
NASDAQ Welcomes Chimerix, Inc. to The NASDAQ Stock Market
The NASDAQ OMX Group, Inc.
The NASDAQ OMX Group, Inc. announces an IPO of Chimerix (CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need.   more >>
News archive >>

 
 
© Helix Ventures 2008 – 2015   /   about us   /   portfolio   /   team   /   news   /   contact us